Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics
May 07 2021 - 7:30AM
Business Wire
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX)
("Brooklyn"), a biopharmaceutical company focused on exploring the
role that cytokine and gene editing/cell therapy can have in
treating patients with cancer, blood disorders and monogenic
diseases, today announced the appointment of Erich Mohr, Ph.D.,
ICD.D. to Brooklyn’s Board of Directors, effective May 7, 2021.
“Dr. Erich Mohr’s distinguished career as a leader of life
sciences companies, as well as in academic research, will serve as
an important resource to Brooklyn,” said Howard J. Federoff, M.D.,
Ph.D. Brooklyn ImmunoTherapeutics’ Chief Executive Officer and
President. “Dr. Mohr has a proven track record of creating value
both as a Board member and as a senior executive in a number of
life sciences companies. I am delighted to welcome Erich to our
board.”
“I am excited to join Brooklyn’s board at such a pivotal time in
the company’s growth,” said Dr. Mohr. “I am drawn to Brooklyn by
the progress of IRX-2, a cytokine-based drug candidate which is
currently being studied in multiple clinical trials both as a
monotherapy and in combination with other anti-cancer therapies.
Brooklyn has also successfully licensed leading edge gene editing
technology which could open the door to developing therapies to
treat a variety of cancer and blood disorders. I look forward to
supporting the company’s clinical plans and business plans to help
Brooklyn achieve its full potential.”
Dr. Mohr currently serves as Chairman of Oak Bay Biosciences as
well as Chairman & Chief Executive Officer of MedGenesis
Therapeutix Inc. Previously, he served as Chief Scientific Officer
of PRA International and Chief Executive Officer of CroMedica
International. He earned his Bachelors degree in Chemistry/Biology
from the University of the Pacific and his Ph.D. in Neuropsychology
from the University of Victoria.
About Brooklyn ImmunoTherapeutics
Brooklyn is exploring the role that cytokine-based therapy can
have in treating patients with cancer, both as a single agent and
in combination with other anti-cancer therapies. The company is
also exploring opportunities to advance oncology, blood disorder,
and monogenic disease therapies using leading edge gene
editing/cell therapy technology through the newly acquired license
from Factor Bioscience and Novellus.
Brooklyn’s most advanced program is studying the safety and
efficacy of IRX-2 in patients with head and neck cancer. In a Phase
2A clinical trial in head and neck cancer, IRX-2 demonstrated an
overall survival benefit. Additional studies are either underway or
planned in other solid tumor cancer indications.
For more information about Brooklyn and its clinical programs,
please visit www.BrooklynITx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210507005071/en/
Media Contact MacDougall Nicholas Chang 781-235-3060
nchang@macbiocom.com
IR Contact CORE IR 516-222-2560
investors@brooklynitx.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024